Stanley R. Frankel

Stanley (Stan) Frankel joined BMS in 2019 as Senior Vice President of Cellular Therapy Development and remained through 2020 as part of the transition of the Celgene acquisition by BMS.

Before joining BMS, Dr. Frankel worked at Celgene since April 2015 as Corporate Vice President, Head of Immuno-oncology, Clinical Research, and Development at Celgene. He has overseen the durvalumab alliance with Medimmune/AstraZeneca, the tislelizumab alliance with BeiGene, and the initial Celgene clinical development alliance with Juno Therapeutics. He was co-chair for the Hematology/Oncology Development Committee. He has been the Hematology/Oncology Clinical Development representative on the Hematology/Oncology Franchise Leadership Team. He served as the Head of the Cellular Therapy Center of Excellence and chairs the Celgene Protocol Review Committee.

Dr. Frankel received his B.A. from Harvard College and his M.D. from Northwestern University. He received his post-graduate training at Mount Sinai Hospital in New York and Memorial Sloan-Kettering Cancer Center where he was Chief Fellow. He had an academic practice in stem cell transplantation and hematologic malignancy clinical trials at Roswell Park Cancer Center, Georgetown University, and the University of Maryland. Dr. Frankel is a Diplomate of the American Board of Internal Medicine with subspecialty credentials in Hematology and Medical Oncology. He is also an Adjunct Associate Professor of Medicine at the Vagelos College of Physicians and Surgeons at Columbia University and licensed to practice in New York. He is a Fellow of the American College of Physicians. He is a member of ACP, AACR, ASTCT, ASCO, ASH, EHA, and ESMO. He has authored more than 80 peer-reviewed scientific papers.

Dr. Frankel has previously led hematology and oncology development programs across a broad range of disease indications in all phases of clinical development at Genta Therapeutics, Merck Research Labs, Roche, Micromet, and Amgen since 2000.

In addition to his contributions to the approval of Blincyto and Zolinza, and the soon anticipated approvals of list-cel and ide-cel, Dr. Frankel worked as an academic investigator on the development of 11 other approved oncology drugs including Vesanoid and Trisenox for acute promyelocytic leukemia, Rituxan, Zevalin, Bexxar for CD20 expressing malignancies, Neulasta, Kepivance, Mylotarg, and Gleevec. Dr. Frankel has internationally recognized clinical expertise in clinical trials and the treatment of hematologic malignancies including APL, ALL, lymphoma, and Waldenstrom’s macroglobulinemia.